Showing 7391-7400 of 8161 results for "".
- Syneron Candela's PicoWay Picosecond Laser Receives U.S. FDA Clearance for Ultra-Short 785nm Wavelengthhttps://practicaldermatology.com/news/syneron-candelas-picoway-picosecond-laser-receives-us-fda-clearance-for-ultra-short-785nm-wavelength/2458489/And then there were three. The U.S. Food and Drug Administration (FDA) has cleared Syneron Medical Ltd.’s PicoWay® picosecond laser for a new ultra-short 785nm wavelength. The addition of the new
- Summer 2016's Must-Have Accessory: La Roche-Posay's New UV Patch Available Nowhttps://practicaldermatology.com/news/summer-2016s-must-have-accessory-la-roche-posays-new-uv-patch-available-now/2458491/La Roche-Posay’s new UV patch monitor and companion app are here. My UV Patch measures UV exposure in real time. The water- and sweat-resistant patch can be used for up to three days during all outdoor activities. It is approximately one square inch and 50 micrometers thick &n
- Is 'Mitoiron Claw' the Next Great Sunscreen Ingredient?https://practicaldermatology.com/news/is-mitoiron-claw-the-next-great-sunscreen-ingredient/2458493/A new compound that blocks excess free iron in the mitochondria may offer dramatic protection against Ultraviolet A (UVA) radiation in sunlight, according to scientists at the University of Bath and King's College London. Most sunscreens protect well against solar Ultraviolet B
- CeraVe: Suncare Products Get Skin Cancer Foundation Seal of Recommendationhttps://practicaldermatology.com/news/cerave-suncare-products-get-skin-cancer-foundation-seal-of-recommendation/2458495/Two products from Valeant Consumer Healthcare's CeraVe skincare line have received The Skin Cancer Foundation (SCF) Seal of Recommendation for sunscreens. CeraVe® AM Facial Moisturizing Lotion with SPF 30 has earned the “Daily Use” Seal and CeraVe
- FDA Advisory Arm Recommends Brodalumab For Moderate-To-Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-advisory-arm-recommends-brodalumab-for-moderate-to-severe-plaque-psoriasis/2458497/A US. Food and Drug Administration (FDA) advisory panel voted to greenlight Valeant’s IL-17 blocker brodalumab for the treatment of moderate-to-severe plaque psoriasis in adults. The committee voted 18 to 0 in favor of brodalumab injection, 210
- ASDS: Interest in Cosmetic Surgery On the Risehttps://practicaldermatology.com/news/asds-interest-in-cosmetic-surgery-on-the-rise/2458498/Nearly six in 10 individuals are considering a cosmetic medical procedure today, up 50 percent since 2013, according to the annual American Society for Dermatologic Surgery (ASDS) Consumer Survey on Cosmetic Dermatologic Procedur
- Revance's Injectable Toxin to Enter Phase 3 Trialshttps://practicaldermatology.com/news/revances-injectable-toxin-to-enter-phase-3-trials/2458500/It’s game on for Revance Therapeutics, Inc. The company expects to initiate Phase 3 clinical trials of Injectable DaxibotulinumtoxinA (RT002) for the treatment of glabellar lines in the second half of 2016. Revance is moving forward with an
- FDA Greenlights First-Ever OTC Retinoidhttps://practicaldermatology.com/news/fda-greenlights-first-ever-otc-retinoid/2458507/The U.S. Food and Drug Administration (FDA) approved Differin Gel 0.1% (adapalene), a once-daily topical gel for the over-the-counter (OTC) treatment of acne in people 12 years of age and older. Differin Gel 0.1% is the first retinoid to be made available OTC for the
- Sciton Launches New Program to Encourage Practice Growthhttps://practicaldermatology.com/news/sciton-launches-new-program-to-encourage-practice-growth/2458510/Sciton Inc. is unveiling their new practice support program. With Success Builder, Sciton offers four specialized pillars: clinical training, marketing tools, business development, and Sciton-sanctioned tools and courses. Many of the vendors also o
- Valeant Terminates European Licensing Rights for Brodalumabhttps://practicaldermatology.com/news/valeant-terminates-european-licensing-rights-for-brodalumab/2458512/Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patients with moderate-to-severe plaque psoriasis, to terminate Valeant's right to develop and comme